Recursion Pharmaceuticals (RXRX) Profit After Tax (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Profit After Tax data on file, last reported at -$117.5 million in Q1 2026.

• Quarterly Profit After Tax rose 41.97% year-over-year to -$117.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$559.8 million (up 2.61% YoY) and the FY2025 annual result came in at -$644.8 million, down 39.06% from the prior year.
• Profit After Tax retreated to -$117.5 million in Q1 2026, from -$108.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$56.0 million in Q1 2022 to a low of -$202.5 million in Q1 2025.
• A 5-year average of -$105.5 million and a median of -$93.0 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax slumped 121.6% — and 2026, when it soared 41.97%.
• Tracing RXRX's Profit After Tax over 5 years: stood at -$57.5 million in 2022, then tumbled by 61.75% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then jumped by 39.56% to -$108.1 million in 2025, then slipped by 8.68% to -$117.5 million in 2026.
• The last three Profit After Tax figures came in at -$117.5 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.3 million (Q3 2025), per Business Quant data.